US20250179450A1
University of Texas System
CRISPR/Cas9-mediated genome editing holds clinical potential for treating genetic diseases, such as Duchenne muscular dystrophy (DMD), which is caused by mutations in the dystrophin gene. Here, an improved variant of SpCas9 is provided that exhibits increase capacity to target genomic loci and …